212 related articles for article (PubMed ID: 14624433)
1. The porcine coronary model of in-stent restenosis: current status in the era of drug-eluting stents.
Lowe HC; Schwartz RS; Mac Neill BD; Jang IK; Hayase M; Rogers C; Oesterle SN
Catheter Cardiovasc Interv; 2003 Dec; 60(4):515-23. PubMed ID: 14624433
[TBL] [Abstract][Full Text] [Related]
2. Drug-eluting stents: preventing restenosis.
Slavin L; Chhabra A; Tobis JM
Cardiol Rev; 2007; 15(1):1-12. PubMed ID: 17172878
[TBL] [Abstract][Full Text] [Related]
3. Drug-eluting stents.
García-García HM; Vaina S; Tsuchida K; Serruys PW
Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
Grube E; Buellesfeld L
Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
[TBL] [Abstract][Full Text] [Related]
5. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis.
Airoldi F; Briguori C; Iakovou I; Stankovic G; Biondi-Zoccai G; Carlino M; Chieffo A; Montorfano M; Cosgrave J; Michev I; Rogacka R; Sangiorgi GM; Colombo A
Am J Cardiol; 2006 Apr; 97(8):1182-7. PubMed ID: 16616023
[TBL] [Abstract][Full Text] [Related]
6. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
Beijk MA; Piek JJ
Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
[TBL] [Abstract][Full Text] [Related]
7. Experimental efficacy of an everolimus eluting cobalt chromium stent.
Carter AJ; Brodeur A; Collingwood R; Ross S; Gibson L; Wang CA; Haller S; Coleman L; Virmani R
Catheter Cardiovasc Interv; 2006 Jul; 68(1):97-103. PubMed ID: 16755598
[TBL] [Abstract][Full Text] [Related]
8. Drug-eluting stents: from randomized trials to the real world.
Saia F; Degertekin M; Lemos PA; Serruys PW
Minerva Cardioangiol; 2004 Oct; 52(5):349-63. PubMed ID: 15514571
[TBL] [Abstract][Full Text] [Related]
9. Understanding the drug-eluting stent trials.
Coolong A; Kuntz RE
Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
[TBL] [Abstract][Full Text] [Related]
10. Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis.
Silva GV; Fernandes MR; Madonna R; Clubb F; Oliveira E; Jimenez-Quevedo P; Branco R; Lopez J; Angeli FS; Sanz-Ruiz R; Vaughn WK; Zheng Y; Baimbridge F; Canales J; Cardoso CO; Assad JA; Falotico R; Perin EC
Catheter Cardiovasc Interv; 2009 May; 73(6):801-8. PubMed ID: 19309735
[TBL] [Abstract][Full Text] [Related]
11. Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies?
Silber S
J Interv Cardiol; 2004 Dec; 17(6):375-85. PubMed ID: 15546289
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.
Ge J; Qian J; Wang X; Wang Q; Yan W; Yan Y; Fan B; Ge L; Liu X
Catheter Cardiovasc Interv; 2007 Feb; 69(2):198-202. PubMed ID: 17195205
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
[TBL] [Abstract][Full Text] [Related]
14. Release profiles in drug-eluting stents: issues and uncertainties.
Venkatraman S; Boey F
J Control Release; 2007 Jul; 120(3):149-60. PubMed ID: 17582635
[TBL] [Abstract][Full Text] [Related]
15. [Drug-eluting stents and other anti-restenosis devices].
Moreno R
Rev Esp Cardiol; 2005 Jul; 58(7):842-62. PubMed ID: 16022816
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating.
Wessely R; Hausleiter J; Michaelis C; Jaschke B; Vogeser M; Milz S; Behnisch B; Schratzenstaller T; Renke-Gluszko M; Stöver M; Wintermantel E; Kastrati A; Schömig A
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):748-53. PubMed ID: 15681298
[TBL] [Abstract][Full Text] [Related]
17. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
Buellesfeld L; Grube E
Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589
[TBL] [Abstract][Full Text] [Related]
18. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial.
Morice MC; Serruys PW; Barragan P; Bode C; Van Es GA; Stoll HP; Snead D; Mauri L; Cutlip DE; Sousa E
J Am Coll Cardiol; 2007 Oct; 50(14):1299-304. PubMed ID: 17903626
[TBL] [Abstract][Full Text] [Related]
19. Early experiences and clinical implications of restenosis and drug-eluting stents: Part 2.
Chong PH; Cheng JW
Ann Pharmacother; 2004 May; 38(5):845-52. PubMed ID: 15039482
[TBL] [Abstract][Full Text] [Related]
20. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating.
Hausleiter J; Kastrati A; Wessely R; Dibra A; Mehilli J; Schratzenstaller T; Graf I; Renke-Gluszko M; Behnisch B; Dirschinger J; Wintermantel E; Schömig A;
Eur Heart J; 2005 Aug; 26(15):1475-81. PubMed ID: 15975990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
